Spero Therapeutics, Inc. (NASDAQ:SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for
Rice Acquisition Corp. (NYSE:RICE) ("RAC"), a special purpose acquisition company focused on the energy transition sector, today announced that it will hold a special meeting of stockholders (the